Clinical Trials Sponsored by Cic bioGune

Total 6177 results

Biogen

Withdrawn

Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)

Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen

Terminated

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants (RESPOND-EXT)

Rheumatoid Arthritis

Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russian Federation, United Kingdom
Biogen

Terminated

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Biogen

Withdrawn

Systemic Sclerosis Clinical and Biomarker Study

Healthy | Systemic Sclerosis
Biogen

Completed

Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study (AVAIL)

Multiple Sclerosis

Belgium
Biogen

Completed

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

Healthy

United States, Italy, France
Biogen

Terminated

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

France, United States, Belgium, Australia, Austria, Poland, Canada, United Kingdom
Biogen

Completed

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Biogen

Completed

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

GIST

United States
Biogen

Completed

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy (SPRINT)

Sciatica | Radiculopathy | Painful Lumbar Radiculopathy

United States
Biogen

Completed

Single-Dose Study of a New Formulation of BIIB061

Multiple Sclerosis

United States
Biogen

Completed

TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World (TYGRIS - ROW)

Multiple Sclerosis

Germany
Biogen

Completed

Canadian Avonex PEN Productivity Study (CAPPS)

Multiple Sclerosis

Canada
Biogen

Completed

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Multiple Sclerosis

United States
Biogen

Completed

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (ADVANCE)

Relapsing Multiple Sclerosis

United States, Germany, Russian Federation, India, New Zealand, Spain, Belgium, Colombia, Canada, Bulgaria, Serbia, Greece, Peru, Ukraine, Poland, United Kingdom, Croatia, France, Romania, Chile, Czech Republic, Mexico, Estonia, Georgia, Latv... and more
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Biogen

Completed

Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (PERSIST)

Multiple Sclerosis

Sweden, France, United Kingdom, Germany, Denmark, Netherlands, Slovakia, Switzerland, Norway, Portugal
Biogen

Completed

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Multiple Sclerosis | Pregnancy | Prenatal Exposure Delayed Effects

United States
Biogen

Terminated

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

Multiple Sclerosis

United States
Biogen

Completed

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

Healthy

United States
Biogen

Completed

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Singapore, Taiwan, United Kingdom
Biogen

Completed

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Czech Republic, Poland, Slovakia, India, Australia, Canada
Biogen

Completed

Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Biogen

Completed

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Biogen

Terminated

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance (CHAMPIONS CONT)

Multiple Sclerosis

United States
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
Biogen

Completed

A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects

Healthy

China
Biogen

Completed

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

Healthy Volunteers

United States
Biogen

Completed

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Australia, Canada, United Kingdom
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Biogen

Completed

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Sweden, Czech Republic, France, Russian Federation, Turkey, United Kingdom, Germany, Lithuania, Romania, United States, Austria
Biogen

Completed

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Lymphoma | Tumors

United Kingdom, United States
Biogen

Completed

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Colorectal Carcinoma | Metastases

United States
Biogen

Completed

Open-Label Safety Extension Study of Avonex

Multiple Sclerosis
Biogen

Completed

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Multiple Sclerosis
Biogen

Terminated

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose (TODAY)

Relapsing Remitting Multiple Sclerosis

Australia
Biogen

Completed

Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies (RECOVER)

Relapsing-Remitting Multiple Sclerosis

Finland
Biogen

Completed

Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, United States
Biogen

Completed

A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Biopure Corporation

Completed

Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization

Acute Coronary Syndrome | Coronary Occlusion

Netherlands
Biopure Corporation

Unknown

A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery

Coronary Artery Disease

Greece, South Africa, United Kingdom
Biopure Corporation

Terminated

Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia

Peripheral Vascular Disease

United Kingdom, South Africa
Biopure Corporation

Unknown

A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects

Wounds and Injuries

South Africa
Biogen

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Healthy Volunteer

United States
Biogen

Recruiting

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis (FUSION)

Relapsing Forms of Multiple Sclerosis

Spain, United States, Italy, Switzerland, Germany, Bulgaria, Czechia, Poland, Puerto Rico, Romania
Biogen

Recruiting

A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Multiple Sclerosis

United States
Biogen

Recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis

Spain, Ireland, United States, Germany
Biogen

Recruiting

Adult Spinal Muscular Atrophy (SMA) China Registry

Muscular Atrophy, Spinal

China
Biogen

Recruiting

A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus

United States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hungary, Puerto... and more
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden

3

Subscribe